Jaguar Health names Principal Investigators for Canalevia-CA1 trial

Jaguar Health announced that two leading veterinary oncologists, Laura D. Garrett, DVM, Diplomate ACVIM and Angharad Waite, VMD, DACVIM will serve as Principal Investigators for the company’s planned clinical field study of Canalevia-CA1, the company’s U.S. Food and Drug Administration conditionally approved prescription drug for the treatment of chemotherapy-induced diarrhea in dogs, to support full approval of the product. Canalevia-CA1 received conditional approval in December 2021 from the FDA for the treatment of CID in dogs and is available from multiple leading veterinary distributors in the U.S. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval.